

CORRECTION

Open Access



Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth

Jing Qian^{1,8}, Yanxia Ma^{1,7}, William M. Tahaney^{1,2,6}, Cassandra L. Moyer¹, Amanda Lanier¹, Jamal Hill¹, Darian Coleman¹, Negar Koupaei^{1,4}, Susan G. Hilsenbeck³, Michelle I. Savage¹, Brent D. G. Page⁵, Abhijit Mazumdar¹ and Powel H. Brown^{1,2*}

Qian et al. *Breast Cancer Research* (2024) 26:23
<https://doi.org/10.1186/s13058-024-01778-w>

The original article has incomplete funding information with regard to author Negar Koupaei. The complete funding note is as follows:

Funding

This work was funded by a Susan G Komen Promise Grant (KG081694 P.H.B.), a Komen SAB Grant (9SAB12-00006, P.H.B.), and a CCSG Grant (P30 CA016672, P.H.B.). This work was also supported by the John Charles Cain Endowment (P.H.B.). Negar Koupaei (NK)

was supported by the 1R25CA240137-01A1 UPWARDS Training Program and by the CPRIT Research Training Award CPRIT Training Program (RP210028).

The original article [1] has been corrected.

Published online: 26 March 2024

References

1. Qian J, Ma Y, Tahaney WM, et al. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. *Breast Cancer Res.* 2024;26:23. <https://doi.org/10.1186/s13058-024-01778-w>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s13058-024-01778-w>.

*Correspondence:

Powel H. Brown
PHBrown@mdanderson.org

¹Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

²Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA

³Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA

⁴Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

⁶Monte Rosa Therapeutics, Boston, USA

⁷Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁸The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.